Treatment with new oral anticoagulants in primary care practices

• Conditions: I48; Atrial fibrillation and flutter

• Registration Number: DRKS00006862
• Lead Sponsor: niversitätsklinikum Bonn

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03-06
• Study Completion: 2015-05-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 353

Inclusion Criteria

GP patients who have been prescribed in the past two years one of the drugs of Pradaxa, Xarelto and Eliquis

Exclusion Criteria

Duration of warfarin-taking before changing to the new oral anticoagulants <6 months

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TTR at the time of a change from VKA to NOAK<br>(calculation with a formula including INR values)<br>

Secondary Outcome Measures

Name	Time	Method
Reason for the change of VKA to NOAK<br>(information from the electronic patient data or personal conversation with the concerned doctor)